{"id":946195,"date":"2026-03-23T08:33:47","date_gmt":"2026-03-23T12:33:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/"},"modified":"2026-03-23T08:33:47","modified_gmt":"2026-03-23T12:33:47","slug":"bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/","title":{"rendered":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON, March  23, 2026  (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day.<\/p>\n<p align=\"justify\">Individuals may register for the conference call by clicking the link <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t-WQ-BbHr4Rih-2J9UMZ-AC5bqwdv-i8wPH749EaQlaO5B1kXLC87UiVyBo6oGIoPoP6Cjx037NF_5JWXtUri_tUQAOHQeHYyUfpKIlc9pvwjEwnEU4LHUT5_MR9i3uUsQgoUNbyFqPk1M47uDagTwvr8aL9HFQdjutN62pTmu8=\" rel=\"nofollow\" target=\"_blank\">here<\/a>. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GKspgxPdro-8VkppJ3Hq89-cFjopJQqwyynJdDw0OV36GKwSwhr_frSa2jxLw0BnwfuPom3NRSvmwpQ_YQe2YH7eRvQa8A6zdDPVMQ2X34T8fdh5RwK1ZNswSAYVT1SvOJ7Q0jF6VFStBX-UWSZr-Q==\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.<\/p>\n<p align=\"justify\">\n        <strong>About Bicara Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (\u201cTGF-\u03b2\u201d). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-\u03b2 signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Rachel Frank<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=chgn3HOf9A3DRSlKVsfdg9rW_m6O6oiaPwyO-Ux5vxK600l-RwjnFYQSQ3rDa8tdFYcJnt8yrpgmMr-c0ggQBw==\" rel=\"nofollow\" target=\"_blank\">IR@bicara.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Amanda Lazaro<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=la0mRvMk4QB2GinFrD9P3vCFkqFx4QUYDEjhC3wKDx0YKY0iprEnbZe05UKd76ffIlp1iBBmAmy-wHmGJ70Ere0HrlyFEDxwuqLV9RUD6qY=\" rel=\"nofollow\" target=\"_blank\">Amanda@1abmedia.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmQxZjUxYWMtOGNmYy00ZjVhLWJlMWYtNDBmZjgzZmZhOGYwLTEyNjI0MjctMjAyNi0wMy0yMy1lbg==\/tiny\/Bicara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, March 23, 2026 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the \u201cEvents &amp; Presentations\u201d section within the Investors &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946195","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 23, 2026 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the \u201cEvents &amp; Presentations\u201d section within the Investors &hellip; Continue reading &quot;Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T12:33:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET\",\"datePublished\":\"2026-03-23T12:33:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/\"},\"wordCount\":301,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/\",\"name\":\"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=\",\"datePublished\":\"2026-03-23T12:33:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/","og_locale":"en_US","og_type":"article","og_title":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Market Newsdesk","og_description":"BOSTON, March 23, 2026 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the \u201cEvents &amp; Presentations\u201d section within the Investors &hellip; Continue reading \"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-23T12:33:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET","datePublished":"2026-03-23T12:33:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/"},"wordCount":301,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/","name":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=","datePublished":"2026-03-23T12:33:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NTg1OSM3NDk2MDA1IzIyNTA4NzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946195"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}